Changes in opioid use and healthcare costs among U.S. patients with diabetic peripheral neuropathic pain treated with duloxetine compared with other therapies

References

• Cole BE. Diabetic peripheral neuropathic pain: recognition and management. Pain Med 2007;8(Suppl. 2):S27-32
   PubMed Web of Science ®Google Scholar
• Galer BS, Gianas A, Jensen MP. Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life. Diabetes Res Clin Pract 2000;47:123-8
   PubMed Web of Science ®Google Scholar
• Argoff CE, Cole BE, Fishbain DA, et al. Diabetic peripheral neuropathic pain: clinical and quality-of-life issues. Mayo Clin Proc 2006;81:S3-11
   PubMed Web of Science ®Google Scholar
• Boulton AJ, Malik RA, Arezzo JC, et al. Diabetic somatic neuropathies. Diabetes Care 2004;27:1458-86
   PubMed Web of Science ®Google Scholar
• Boulton AJ. Management of Diabetic Peripheral Neuropathy, 23rd edn. 2005: 9-15
   Google Scholar
• Benbow SJ, Wallymahmed ME, MacFarlane IA. Diabetic peripheral neuropathy and quality of life. QJM 1998;91:733-7
   PubMed Web of Science ®Google Scholar
• Gore M, Brandenburg NA, Dukes E, et al. Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep. J Pain Symptom Manag 2005;30:374-85
   PubMed Web of Science ®Google Scholar
• Jensen MP, Chodroff MJ, Dworkin RH. The impact of neuropathic pain on health-related quality of life: review and implications. Neurology 2007;68:1178-82
   PubMed Web of Science ®Google Scholar
• Boulanger L, Zhao Y, Bao Y, et al. A retrospective study on the impact of comorbid depression or anxiety on healthcare resource use and costs among diabetic neuropathy patients. BMC Health Serv Res 2009;9:111
   PubMed Web of Science ®Google Scholar
• Candrilli SD, Davis KL, Kan HJ, et al. Prevalence and the associated burden of illness of symptoms of diabetic peripheral neuropathy and diabetic retinopathy. J Diabetes Complications 2007;21:306-14
   PubMed Web of Science ®Google Scholar
• Gore M, Brandenburg NA, Hoffman DL, et al. Burden of illness in painful diabetic peripheral neuropathy: the patients’ perspectives. J Pain 2006;7:892-900
   PubMed Web of Science ®Google Scholar
• Currie CJ, Poole CD, Woehl A, et al. The health-related utility and health-related quality of life of hospital-treated subjects with type 1 or type 2 diabetes with particular reference to differing severity of peripheral neuropathy. Diabetologia 2006;49:2272-80
   PubMed Web of Science ®Google Scholar
• Boulanger L, Zhao Y, Foster TS, et al. Impact of comorbid depression or anxiety on patterns of treatment and economic outcomes among patients with diabetic peripheral neuropathic pain. Curr Med Res Opin 2009;25:1763-73
   PubMed Web of Science ®Google Scholar
• Diabetic peripheral neuropathic pain. Consensus guidelines for treatment. J Fam Pract 2006;Suppl:3-19
   Google Scholar
• Argoff CE, Backonja MM, Belgrade MJ, et al. Consensus guidelines: treatment planning and options. Diabetic peripheral neuropathic pain. Mayo Clin Proc 2006;81:S12-25
   PubMed Web of Science ®Google Scholar
• Wu EQ, Birnbaum HG, Mareva MN, et al. Cost-effectiveness of duloxetine versus routine treatment for U.S. patients with diabetic peripheral neuropathic pain. J Pain 2006;7:399-407
   PubMed Web of Science ®Google Scholar
• Benyamin R, Trescot AM, Datta S, et al. Opioid complications and side effects. Pain Physician 2008;11:S105-20
   PubMed Web of Science ®Google Scholar
• Jensen TS, Backonja MM, Hernandez JS, et al. New perspectives on the management of diabetic peripheral neuropathic pain. Diab Vasc Dis Res 2006;3:108-19
   PubMedGoogle Scholar
• Robinson-Papp J, Simpson DM. Safety profile of treatment in diabetic peripheral neuropathic pain. Pain Med 2007;8(Suppl. 2):S43-9
   PubMed Web of Science ®Google Scholar
• Braden JB, Fan MY, Edlund MJ, et al. Trends in use of opioids by noncancer pain type 2000–2005 among Arkansas Medicaid and HealthCore enrollees: results from the TROUP study. J Pain 2008;9:1026-35
   PubMed Web of Science ®Google Scholar
• Bureau of Labor Statistics. Consumer Price Index. January 2008. 2010
   Google Scholar
• Sullivan MD, Edlund MJ, Fan MY, et al. Trends in use of opioids for non-cancer pain conditions 2000–2005 in commercial and Medicaid insurance plans: the TROUP study. Pain 2008;138:440-9
   PubMed Web of Science ®Google Scholar
• Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol 1997;50:105-16
   PubMed Web of Science ®Google Scholar
• Andrade SE, Kahler KH, Frech F, et al. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 2006;15:565-74
   PubMed Web of Science ®Google Scholar
• Afifi AA, Kotlerman JB, Ettner SL, et al. Methods for improving regression analysis for skewed continuous or counted responses. Annu Rev Public Health 2007;28:95-111
   PubMed Web of Science ®Google Scholar
• McCullagh P, Nelder JA. Generalized Linear Models, 2nd edn. London: Chapman and Hall, 1989
   Google Scholar
• Efron B, Tibhirani R. An introduction to the bootstrap. New York: Chapman and Hall, 1993
   Google Scholar
• Gilson AM, Ryan KM, Joranson DE, et al. A reassessment of trends in the medical use and abuse of opioid analgesics and implications for diversion control: 1997–2002. J Pain Symptom Manag 2004;28:176-88
   PubMed Web of Science ®Google Scholar
• Wu N, Chen S, Boulanger L, et al. Duloxetine compliance and its association with healthcare costs among patients with diabetic peripheral neuropathic pain. J Med Econ 2009;12:192-202
   PubMedGoogle Scholar
• Boulton AJ. Treatment of symptomatic diabetic neuropathy. Diabetes Metab Res Rev 2003;19(Suppl. 1):S16-21
   PubMed Web of Science ®Google Scholar